UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Link zum Volltext

Verfügbarkeit prüfen

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008-07, Vol.4 (5), p.731-733

Karantza, Vassiliki

2008

Link zum Volltext

Verfügbarkeit prüfen

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Link zum Volltext

Verfügbarkeit prüfen

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Methods in Enzymology, 2008, Vol.446, p.61-76

2008

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

The Lancet (British edition), 2021-07, Vol.398 (10294), p.24-25

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653

2021

Link zum Volltext

Verfügbarkeit prüfen

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Methods in Enzymology, 2009, Vol.453, p.53-81

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Link zum Volltext

Verfügbarkeit prüfen

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-09-05

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-01-GS1-01

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-04-PD14-04

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD14-07-PD14-07

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.GS3-01-GS3-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Thermodynamic Studies of the Core Histones: pH and Ionic Strength Effects on the Stability of the (H3−H4)/(H3−H4)2 System

Biochemistry (Easton), 1996-02, Vol.35 (6), p.2037-2046

1996

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study

European journal of surgical oncology, 2022-02, Vol.48 (2), p.e30-e31

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.3545-3545

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-225-LB-225

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-138: Autophagy regulator BECN1 acts as a context-dependent tumor suppressor opposing parity-associated and WNT1-driven mammary tumorigenesis

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-138-LB-138

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract A004: Expansion of immature mammary epithelial populations promotes Wnt1 -driven mammary tumorigenesis in an autophagy-deficient mouse model

Molecular cancer research, 2013-10, Vol.11 (10_Supplement), p.A004-A004

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(36)

Publikationsform

Sprache

Englisch
(40)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Abstract PD14-04: Contribution of tumor and immune cells to PD-L1 as a predictive biomarker in triple-negative breast cancer (TNBC): Analysis from KEYNOTE-119

Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

Thermodynamic Studies of the Core Histones: pH and Ionic Strength Effects on the Stability of the (H3−H4)/(H3−H4)2 System

Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study

Abstract 3545: Autophagy inhibition as a therapeutic strategy in cancer

Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086

Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119

Abstract LB-138: Autophagy regulator BECN1 acts as a context-dependent tumor suppressor opposing parity-associated and WNT1-driven mammary tumorigenesis

Abstract A004: Expansion of immature mammary epithelial populations promotes Wnt1 -driven mammary tumorigenesis in an autophagy-deficient mouse model

Aktive Filter

Suchergebnisse filtern